Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN mutant |
| Therapy | GSK2636771 |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN mutant | Advanced Solid Tumor | no benefit | GSK2636771 | Phase II | Actionable | In a Phase II trial (MATCH), GSK2636771 treatment did not meet the primary endpoint of objective response in patients with advanced solid tumors harboring PTEN mutation or deletion but retained protein expression, resulting in stable disease in 32% (7/24) of the patients, a median progression-free survival of 1.8 months, and a median overall survival of 7.5 months (PMID: 40865033; NCT02465060). | 40865033 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40865033) | PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. | Full reference... |